
The Centre for Disease Control’s “Guidance” document describes 21 things that every health economics study in connection with vaccines must do. But the Food and Drug Administration’s (FDA) woeful risk-benefit analysis in connection with Pfizer’s Emergency Use Authorisation (EUA) application to inject children aged 5 to 11 with an experimental gene therapy violates many of these principles.
